image
Healthcare - Biotechnology - NASDAQ - FR
$ 5.81
-1.72 %
$ 494 M
Market Cap
-4.5
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one VALN stock under the worst case scenario is HIDDEN Compared to the current market price of 5.81 USD, Valneva SE is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one VALN stock under the base case scenario is HIDDEN Compared to the current market price of 5.81 USD, Valneva SE is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one VALN stock under the best case scenario is HIDDEN Compared to the current market price of 5.81 USD, Valneva SE is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart VALN

image
$8.5$8.5$8.0$8.0$7.5$7.5$7.0$7.0$6.5$6.5$6.0$6.0$5.5$5.5$5.0$5.0$4.5$4.5$4.0$4.0$3.5$3.5Nov '24Nov '24Dec '24Dec '2420252025Feb '25Feb '25Mar '25Mar '25Apr '25Apr '25May '25May '25Jun '25Jun '25
FINANCIALS
170 M REVENUE
10.32%
13.3 M OPERATING INCOME
116.24%
-12.2 M NET INCOME
87.93%
-67.2 M OPERATING CASH FLOW
66.85%
76.9 M INVESTING CASH FLOW
473.65%
30.7 M FINANCING CASH FLOW
-51.36%
52.9 M REVENUE
15.53%
-20.9 M OPERATING INCOME
-67.76%
-37 M NET INCOME
-300.47%
9.53 M OPERATING CASH FLOW
190.87%
4.69 M INVESTING CASH FLOW
130.48%
-4.59 M FINANCING CASH FLOW
-8.85%
Balance Sheet Valneva SE
image
Current Assets 299 M
Cash & Short-Term Investments 168 M
Receivables 35.2 M
Other Current Assets 95.5 M
Non-Current Assets 201 M
Long-Term Investments 0
PP&E 158 M
Other Non-Current Assets 42.9 M
33.65 %7.04 %19.11 %31.62 %8.58 %Total Assets$500.0m
Current Liabilities 115 M
Accounts Payable 12.6 M
Short-Term Debt 23.4 M
Other Current Liabilities 78.6 M
Non-Current Liabilities 204 M
Long-Term Debt 193 M
Other Non-Current Liabilities 11.2 M
3.96 %7.33 %24.65 %60.53 %3.53 %Total Liabilities$318.8m
EFFICIENCY
Earnings Waterfall Valneva SE
image
Revenue 170 M
Cost Of Revenue 98.5 M
Gross Profit 71 M
Operating Expenses 57.7 M
Operating Income 13.3 M
Other Expenses 25.6 M
Net Income -12.2 M
180m180m160m160m140m140m120m120m100m100m80m80m60m60m40m40m20m20m00(20m)(20m)170m(99m)71m(58m)13m(26m)(12m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
41.89% GROSS MARGIN
41.89%
7.86% OPERATING MARGIN
7.86%
-7.22% NET MARGIN
-7.22%
-6.76% ROE
-6.76%
-2.45% ROA
-2.45%
3.48% ROIC
3.48%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Valneva SE
image
150m150m100m100m50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -12.2 M
Depreciation & Amortization 19.6 M
Capital Expenditures -16.4 M
Stock-Based Compensation 7.98 M
Change in Working Capital -11.6 M
Others -92.2 M
Free Cash Flow -83.7 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Valneva SE
image
Wall Street analysts predict an average 1-year price target for VALN of $15 , with forecasts ranging from a low of $15 to a high of $15 .
VALN Lowest Price Target Wall Street Target
15 USD 158.18%
VALN Average Price Target Wall Street Target
15 USD 158.18%
VALN Highest Price Target Wall Street Target
15 USD 158.18%
Price
Max Price Target
Min Price Target
Average Price Target
161614141212101088664422Jul '24Jul '2420252025Jul '25Jul '2520262026Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 18
6. Ownership
Insider Ownership Valneva SE
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. globenewswire.com - 3 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Valneva SE (“Valneva” or the “Company”) (NASDAQ: VALN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. globenewswire.com - 3 months ago
VALN Investors Have Opportunity to Join Valneva SE Fraud Investigation with the Schall Law Firm LOS ANGELES , April 7, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Valneva SE ("Valneva" or "the Company") (NASDAQ: VALN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. prnewswire.com - 3 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN NEW YORK CITY, NY / ACCESS Newswire / April 6, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ:VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 3 months ago
VALN Investors Have Opportunity to Join Valneva SE Fraud Investigation with the Schall Law Firm LOS ANGELES--(BUSINESS WIRE)--VALN Investors Have Opportunity to Join Valneva SE Fraud Investigation with the Schall Law Firm. businesswire.com - 3 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN NEW YORK CITY, NY / ACCESS Newswire / April 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ:VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 3 months ago
Valneva SE Shareholding Declaration - March 2025 Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France). globenewswire.com - 3 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN NEW YORK, NY / ACCESS Newswire / April 2, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ:VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 3 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN NEW YORK, NY / ACCESS Newswire / April 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ:VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 3 months ago
Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above With this extension, IXCHIQ ® , the first vaccine against the chikungunya virus (CHIKV), is now available for administration for individuals 12 years of age and older in the European Union (EU). globenewswire.com - 3 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN NEW YORK , March 31, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Valneva SE ("Valneva" or the "Company") (NASDAQ: VALN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 3 months ago
Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA Saint Herblain (France), March 31, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has submitted a label extension application to the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) to potentially expand the use of its chikungunya vaccine, IXCHIQ®, currently approved in adults1, to adolescents aged 12 to 17 years in the UK. This submission follows the recent positive opinion of the European Medicines Agency (EMA) on extension of IXCHIQ® label to adolescents in the European Union (EU)2. globenewswire.com - 3 months ago
8. Profile Summary

Valneva SE VALN

image
COUNTRY FR
INDUSTRY Biotechnology
MARKET CAP $ 494 M
Dividend Yield 0.00%
Description Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.
Contact 6 rue Alain Bombard, Saint-Herblain, 44800 https://valneva.com
IPO Date May 5, 2021
Employees 713
Officers Dr. Hanneke Schuitemaker Ph.D. Chief Scientific Officer Mr. Vincent Dequenne Chief Operating Officer Ms. Dipal Patel Chief Commercial Officer Ms. Laetitia Bachelot-Fontaine Vice President of Global Communications & European Investor Relations Mr. Franck Grimaud MBA Chief Business Officer Dr. Juan-Carlos Jaramillo M.D. Chief Medical Officer Ms. Kendra Wergin General Counsel & Corporate Secretary Mr. Thomas Lingelbach President, Chief Executive Officer & Director Mr. Peter Buhler Chief Financial Officer Mr. Joshua Drumm Ph.D. Vice President of Investor Relations